Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 870428, 9 pages
http://dx.doi.org/10.1155/2015/870428
Research Article

Tissue Factor in Dermatitis Herpetiformis and Bullous Pemphigoid: Link between Immune and Coagulation System in Subepidermal Autoimmune Bullous Diseases

1Department of Dermatology and Venereology, Medical University of Lodz, Hallera Square 1, 90-497 Lodz, Poland
2Laboratory of Nephropathology, Medical University of Lodz, Pomorska 251 Street, 92-213 Lodz, Poland
3Department of Immunopathology, Faculty of Biomedical Sciences and Postgraduate Training, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland
4Department of Social Medicine, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland
5Department of Laboratory Diagnostics, Medical University of Lodz, Kopcinskiego 22, 90-153 Lodz, Poland

Received 30 August 2015; Revised 27 November 2015; Accepted 10 December 2015

Academic Editor: Sandra Helena Penha Oliveira

Copyright © 2015 Agnieszka Zebrowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Kárpáti, “Dermatitis herpetiformis: close to unravelling a disease,” Journal of Dermatological Science, vol. 34, no. 2, pp. 83–90, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Sárdy, S. Kárpáti, B. Merkl, M. Paulsson, and N. Smyth, “Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis,” The Journal of Experimental Medicine, vol. 195, no. 6, pp. 747–757, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Dieterich, E. Laag, L. Bruckner-Tuderman et al., “Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis,” Journal of Investigative Dermatology, vol. 113, no. 1, pp. 133–136, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Hendrix, K. L. Mangum, J. J. Zone, and W. R. Gammon, “Cutaneous IgA deposits in bullous diseases function as ligands to mediate adherence of activated neutrophils,” Journal of Investigative Dermatology, vol. 94, no. 5, pp. 667–672, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. M. V. Dahl, R. J. Falk, R. Carpenter, and A. F. Michael, “Membrane attack complex of complement in dermatitis herpetiformis,” Archives of Dermatology, vol. 121, no. 1, pp. 70–72, 1985. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Airola, M. Vaalamo, T. Reunala, and U. K. Saarialho-Kere, “Enhanced expression of interstitial collagenase, stromelysin-1, and urokinase plasminogen activator in lesions of dermatitis herpetiformis,” Journal of Investigative Dermatology, vol. 105, no. 2, pp. 184–189, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. R. F. Ghohestani, J. Novotney, M. Chaudhary, and R. S. Agah, “Bullous pemphigoid: from the bedside to the research laboratory,” Clinics in Dermatology, vol. 19, no. 6, pp. 690–696, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Stanley, “Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion,” Advances in Immunology, vol. 53, pp. 291–325, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. R. E. Jordon, E. H. Beutner, E. Witebsky, G. Blumental, W. L. Hale, and W. F. Lever, “Basement zone antibodies in bullous pemphigoid,” Journal of the American Medical Association, vol. 200, no. 9, pp. 751–756, 1967. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Schmidt, S. Reimer, N. Kruse et al., “Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes,” Journal of Investigative Dermatology, vol. 115, no. 5, pp. 842–848, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Zebrowska, M. Wągrowska-Danilewicz, M. Danilewicz et al., “Expression of selected ADAMs in bullous pemphigoid and dermatitis herpetiformis,” Journal of Dermatological Science, vol. 56, no. 1, pp. 58–61, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Cugno, A. V. Marzano, P. Bucciarelli et al., “Increased risk of venous thromboembolism in patients with bullous pemphigoid,” Thrombosis and Haemostasis, vol. 114, no. 6, 2015. View at Publisher · View at Google Scholar
  13. A. V. Marzano, A. Tedeschi, D. Fanoni et al., “Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications,” British Journal of Dermatology, vol. 160, no. 2, pp. 266–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Rico, C. Benning, E. S. Weingart, R. D. Streilein, and R. P. Hall III, “Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris,” British Journal of Dermatology, vol. 140, no. 6, pp. 1079–1086, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Engineer, K. Bhol, S. Kumari, and A. Razzaque Ahmed, “Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation,” Cytokine, vol. 13, no. 1, pp. 32–38, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. B. O. Gerber, M. P. Zanni, M. Uguccioni et al., “Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils,” Current Biology, vol. 7, no. 11, pp. 836–843, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Moosbauer, E. Morgenstern, S. L. Cuvelier et al., “Eosinophils are a major intravascular location for tissue factor storage and exposure,” Blood, vol. 109, no. 3, pp. 995–1002, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. A. Muller, M. H. Ultsch, R. F. Kelley et al., “Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding sile,” Biochemistry, vol. 33, pp. 10864–10867, 1994. View at Google Scholar
  19. A. V. Marzano, A. Tedeshi, D. Spinelli, D. Fanoni, C. Crosti, and M. Cugno, “Coagulation activation in autoimmune bullous diseases,” Clinical & Experimental Immunology, vol. 158, no. 1, pp. 31–36, 2009. View at Publisher · View at Google Scholar
  20. A. V. Marzano, A. Tedeschi, I. Polloni, C. Crosti, and M. Cugno, “Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease,” Clinical and Experimental Immunology, vol. 171, no. 1, pp. 76–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Cunningham, P. Romas, P. Hutchinson, S. R. Holdsworth, and P. G. Tipping, “Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages,” Blood, vol. 94, no. 10, pp. 3413–3420, 1999. View at Google Scholar · View at Scopus
  22. M. Cugno, A. Tedeschi, R. Asero, P. L. Meroni, and A. V. Marzano, “Skin autoimmunity and blood coagulation,” Autoimmunity, vol. 43, no. 2, pp. 189–194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Venge, J. Byström, M. Carlson et al., “Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease,” Clinical and Experimental Allergy, vol. 29, no. 9, pp. 1172–1186, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kita, R. Abu-Ghazaleh, C. J. Sanderson, and G. J. Gleich, “Effect of steroids on immunoglobulin-induced eosinophil degranulation,” The Journal of Allergy and Clinical Immunology, vol. 87, no. 1, pp. 70–77, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Del Prete, M. De Carli, R. M. Lammel et al., “Th1 and Th2 T-helper cells Ebert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes,” Blood, vol. 86, no. 1, pp. 250–257, 1995. View at Google Scholar · View at Scopus
  26. I. Kucharewicz, K. Kowal, W. Buczko, and A. Bodzenta-Łukaszyk, “The plasmin system in airway remodeling,” Thrombosis Research, vol. 112, no. 1-2, pp. 1–7, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. K. So, P. A. Varisco, B. Kemkes-Matthes et al., “Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways,” Journal of Thrombosis and Haemostasis, vol. 1, no. 12, pp. 2510–2515, 2003. View at Google Scholar
  28. K. Kume, M. Yamasaki, M. Tashiro, I. Yoshikawa, and M. Otsuki, “Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis,” Internal Medicine, vol. 46, no. 17, pp. 1323–1330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Levi, T. van der Poll, H. Ten Cate, and S. J. H. van Deventer, “The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia,” European Journal of Clinical Investigation, vol. 27, no. 1, pp. 3–9, 1997. View at Google Scholar · View at Scopus
  30. P. C. Y. Liaw, C. T. Esmon, K. Kahnamoui et al., “Patients with severe sepsis vary markedly in their ability to generate activated protein C,” Blood, vol. 104, no. 13, pp. 3958–3964, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Narbutt, E. Waszczykowska, J. Lukamowicz, A. Sysa-Jedrzejowska, J. Kobos, and A. Zebrowska, “Disturbances of the expression of metalloproteinases and their tissue inhibitors cause destruction of the basement membrane in pemphigoid,” Polish Journal of Pathology, vol. 57, no. 2, pp. 71–76, 2006. View at Google Scholar · View at Scopus
  32. M. Caproni, C. Cardinalli, A. D'Agata, W. Selvaggi, and P. Fabbri, “Serum eosinophil cationic protein, myeloperoxidase, tryptase, eotaxin and Th2-L-like cytokines in dermatitis herpetiformis,” International Archives of Allergy and Immunology, vol. 128, no. 1, pp. 67–72, 2002. View at Google Scholar
  33. E. Marietta, K. Black, M. Camilleri et al., “A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice,” Journal of Clinical Investigation, vol. 114, no. 8, pp. 1090–1097, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. M. Langan, R. Hubbard, K. Fleming, and J. West, “A population-based study of acute medical conditions associated with bullous pemphigoid,” British Journal of Dermatology, vol. 161, no. 5, pp. 1149–1152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Langan, L. Smeeth, R. Hubbard, K. M. Fleming, C. J. P. Smith, and J. West, “Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study,” The British Medical Journal, vol. 337, no. 7662, pp. 160–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. D. J. Brotman, J. P. Girod, A. Posch et al., “Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers,” Thrombosis Research, vol. 118, no. 2, pp. 247–252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Van Zaane, E. Nur, A. Squizzato et al., “Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors,” Journal of Thrombosis and Haemostasis, vol. 8, no. 11, pp. 2483–2493, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Ernst, “Plasma fibrinogen—an independent cardiovascular risk factor,” Journal of Internal Medicine, vol. 227, no. 6, pp. 365–372, 1990. View at Publisher · View at Google Scholar · View at Scopus
  39. R. M. Senior, W. F. Skogen, G. L. Griffin, and G. D. Wilner, “Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B,” Journal of Clinical Investigation, vol. 77, no. 3, pp. 1014–1019, 1986. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Schmidt, E.-B. Bröcker, and M. Goebeler, “Rituximab in treatment-resistant autoimmune blistering skin disorders,” Clinical Reviews in Allergy and Immunology, vol. 34, no. 1, pp. 56–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. Fairley, C. L. Baum, D. S. Brandt, and K. A. N. Messingham, “Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab,” The Journal of Allergy and Clinical Immunology, vol. 123, no. 3, pp. 704–705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Joly, J. Benichou, C. Lok et al., “Prediction of survival for patients with bullous pemphigoid: a prospective study,” Archives of Dermatology, vol. 141, no. 6, pp. 691–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Rzany, K. Partscht, M. Jung et al., “Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age,” Archives of Dermatology, vol. 138, no. 7, pp. 903–908, 2002. View at Google Scholar · View at Scopus
  44. A. Stockman, H. Beele, Y. Vanderhaeghen, and J. M. Naeyaert, “Topical class I corticosteroids in 10 patients with bullous pemphigoid: correlation of the autcome with the severity degree of the disease and review of the literature,” Journal of the European Academy of Dermatology and Venereology, vol. 18, no. 2, pp. 164–168, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Y. Schultz, L. A. Diaz, D. A. Sirois, V. P. Werth, and S. A. Grando, “Generating consensus research goals and treatment strategies for pemphigus and pemphigoid: the 2010 JC Bystryn pemphigus and pemphigoid meeting,” Journal of Investigative Dermatology, vol. 131, no. 7, pp. 1395–1399, 2011. View at Publisher · View at Google Scholar · View at Scopus